SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* 2. Date of Requiring (Month/Date)   Phadke Deepak Shripad 04/12/20		ment	3. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Vanda Pharmaceuticals Inc.</u> [ VNDA ]					
(Last) (First) (Middle) 9605 MEDICAL CENTER DRIVE			4. Relationship of Reporting Perso (Check all applicable) Director	on(s) to Issuer 10% Owner		5. If Amendment, Date of Original Filed (Month/Day/Year)		
SUITE 300			X Officer (give title below) VP of Manufact	Other (spe below)	· 0.	oplicable Line)	/Group Filing (Check	
(Street) ROCKVILLE MD 20850			vi or munulact	uning			y One Reporting Person y More than One erson	
(City) (State) (Zip)								
Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)			Amount of Securities Beneficially Owned (Instr. 4)			4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned     (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securit Underlying Derivative Security		4. Conversio or Exercis	se Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)		
Nonqualified Stock Option (Right to Buy)	08/15/2006 <sup>(1)</sup>	08/15/2015	Common Stock	15,106(3)	0.33(4)	D		
Nonqualified Stock Option (Right to Buy)	12/29/2006 <sup>(2)</sup>	12/29/2015	Common Stock	13,100 <sup>(3)</sup>	4.73(4)	D		

## Explanation of Responses:

1. Exercisable with respect to 25% of the shares on 08/15/06. Exercisable with respect to an additional 2.08333% of the aggregate option share total each month thereafter.

2. Exercisable with respect to 25% of the shares on 12/29/06. Exercisable with respect to an additional 2.08333% of the aggregate option share total each month thereafter.

3. Reflects a 1-for-3.309755 reverse stock split to occur immediately following the effectiveness of the registration statement covering the issuer's initial public offering.

4. Reflects the converted exercise price of each option share pursuant to the 1-for-3.309755 reverse stock split to occur immediately following the effectiveness of the resistration statement covering the issuer's initial public offering.

## <u>/s/ Deepak Phadke</u>

04/12/2006

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.